Pet owners in the United States should check certain veterinary medications from Wedgewood Pharmacy, which has announced a nationwide recall of formulations that may contain insufficient or excessive amounts of their active ingredients, posing health risks to animals.
The company, based in New Jersey, reported a voluntary recall through a statement released on Wednesday by the U.S. Food and Drug Administration (FDA), after detecting inconsistencies in the reliability of certain analyses conducted by its own laboratory.
The measure affects certain veterinary medicines prepared through individualized pharmaceutical formulation, sent between February 18 and October 6, 2026 to veterinary clinics, pharmacies, and other customers across the United States.
This means that people who received medications for their animals during that period may have some of the products included in the recall at home, even if they have not yet reached their expiration date.
The preparations included in the alert encompass various pharmaceutical forms, including powders, pastes, oral suspensions, injectables, ointments, and ophthalmic solutions, ear preparations, topical aerosols, and gels.
These are medications intended for companion animals, horses, exotic species, and animals kept in zoos, as well as wildlife and aquatic animals.
However, the alert does not affect all medications from Wedgewood nor their entire production. The company has identified specific products and batches whose information can be consulted through a search tool set up for this recall.
The identified problem is related to the potency of the preparations, that is, the effective amount of active ingredient they contain.
According to Wedgewood, the inconsistencies in the data from their analytical tests prevent them from having enough confidence that certain products will maintain the expected concentration.
A medication with a potency lower than expected may not adequately treat the animal's illness, while one with an excessive concentration could cause toxicity or an overdose.
The company stated that the issue was identified during its own quality control procedures and decided to withdraw the affected products as a precautionary measure.
Until the announcement on Wednesday, Wedgewood had received 98 complaints related to these medications, seven of which were classified as serious.
In an additional explanation published on their official page, Wedgewood stated that they had not identified an increase in complaints or adverse events related to the affected products, but that they decided to act due to a lack of confidence in certain analytical results.
The withdrawal does not include products intended for animals raised for human consumption, the company clarified.
How can you tell if your pet's medication is affected?
Wedgewood has enabled an official tool to check the products, lot numbers, and expiration dates included in the recall.
Owners can check the identification of the medication they received and compare it with the information available in the search tool. The page allows queries using product references or batch numbers and supports partial searches.
It is not enough to identify the general name of a medication to conclude that it is affected. It is important to check the specific product, its lot, and the expiration date, because the measure is limited to certain preparations.
The announcement does not mean that all veterinary treatments purchased in the United States during that period have issues.
What to do if you have a product included in the recall?
Wedgewood has requested that pet owners who have received any of the affected medications stop using the product, keep it, and contact the service responsible for coordinating the recall.
To address the inquiries, the company hired Sedgwick, a firm specializing in product withdrawal management, which is notifying affected customers via email and postal mail.
The enabled number is 866-562-5931, available Monday through Friday from 8:00 a.m. to 9:00 p.m., and on Saturdays from 9:00 a.m. to 5:00 p.m., Eastern Time.
Wedgewood indicated that it is organizing refunds or replacements for the recalled medications whenever possible.
In the event that the animal is receiving treatment, the company recommends consulting the veterinarian responsible for the prescription to determine how to continue its care and assess appropriate clinical alternatives.
Owners should not modify the dosages on their own or replace the medication with another without veterinary guidance. The choice of any alternative depends on the medical needs of each animal.
Veterinary clinics, pharmacies, and other establishments with affected products should check their inventory, separate the medications included in the recall, and contact Wedgewood service.
In addition to contacting the veterinarian and the company, pet owners can report to the FDA any potential adverse reactions or quality issues with animal medications.
For those with questions about a product purchased during the specified months, the verification method is the official Wedgewood lot finder or the assistance phone number 866-562-5931.
In recent weeks, the FDA has also issued other health alerts related to products marketed in the country.
This Wednesday, warned about the sale of counterfeit eye drops in stores targeting Hispanic consumers in Florida and Georgia.
Some of the analyzed products contained bacteria capable of causing serious eye infections, prompting authorities to recommend suspending their use.
On October 9, it was reported that a liquid supplement for babies sold through Amazon and other platforms was voluntarily recalled after the detection of ethanol, methanol, and isopropanol not listed on its label.
The measure, announced by Pacific Health Sciences and published by the FDA, only affected a batch of Babies' Magic Tea Baby Sleep Gripe Water.
Another incident occurred in July, when four batches of 5 milligram cetirizine, a medication used to treat allergies, were recalled due to possible cross-contamination with ranitidine.
The measure affected certain batches distributed in the United States, without the manufacturer reporting any adverse events associated with those lots up to the time of the announcement.
Related videos:
Filed under: